Opinion|Videos|December 23, 2024
Infection Prevention and Leveraging EHR for Bispecific Therapy Management
Panelists discuss insights on infection prevention protocols and electronic health record (EHR)–based toxicity management strategies for patients receiving bispecific antibody therapies in relapsed/refractory multiple myeloma (RRMM).
Advertisement
Video content above is prompted by the following
- What best practices can you share regarding preventing infection in patients receiving bispecific therapies in RRMM?
- How has your institution leveraged the electronic health record to assist with standardization and management of toxicities seen with bispecific therapies?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IVIG Therapy Reduced Infections by 67% in Patients With Multiple Myeloma
September 19th 2025
- IMS 2025: Shifting Immunotherapies to Outpatient Care for Multiple Myeloma
September 19th 2025
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making
2
ACIP Meeting: Combined MMRV Vaccine, Hepatitis B Vaccine Restricted for Some Age Groups
3
Intelligent Pharmacy: Leveraging AI and Automation to Enhance Patient Care and Pharmacist Roles
4
FDA Approves Keytruda Qlex Subcutaneous Injection for Adult and Pediatric Patients With Solid Tumors
5